The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 25, 2000

Filed:

Jun. 07, 1995
Applicant:
Inventors:

Enzo Paoletti, Delmar, NY (US);

Keith J Limbach, Troy, NY (US);

Assignee:

Virogenetics Corporation, Troy, NY (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K / ; C12P / ; C12N / ; C12N / ;
U.S. Cl.
CPC ...
4241991 ; 4241841 ; 4242291 ; 4242321 ; 435 691 ; 435 693 ; 4351723 ; 4352351 ; 435236 ; 435237 ; 4353201 ; 536 2372 ; 536 241 ;
Abstract

Disclosed and claimed are nucleotides for genes encoding the canine herpesvirus (CHV) gB, gC and gD homologues. These genes encode polypeptides of 879, 459 and 345 amino acids, respectively, which are also disclosed and claimed. The genes are useful as DNA probes or, for preparing PCR primers. The polypeptides are useful in antigenic, immunological or vaccine compositions. The nucleotides can be expressed in any suitable vector system, allowing for production of the polypeptides. Additionally, the vector system containing any or any combination of the nucleotides can be employed in an antigenic, immunological or vaccine composition, such as a poxvirus vector system, e.g., a CHV-vaccinia or avipox virus recombinant, as can the products from expression, i.e., the gB, gC and gD glycoproteins. Antibodies elicited by the glycoproteins or from expression of the vector containing the nucleotide(s) are also useful. Methods for making and using the composition are also disclosed and claimed. Also, specific canarypox-CHV gB, gC and gD recombinants vCP 320, vCP322 and vCP294 and methods for making and using them are also disclosed and claimed.


Find Patent Forward Citations

Loading…